Artículos por temáticas

Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study.

Dorsey ER, Brocht AF, Nichols PE, Darwin KC, Anderson KE, Beck CA, Singh S, Biglan KM, Shoulson I.

J Huntingtons Dis. 2013;2(4):509-15. doi: 10.3233/JHD-130071.

EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease.

Losekoot M, van Belzen MJ, Seneca S, Bauer P, Stenhouse SA, Barton DE; European Molecular Genetic Quality Network (EMQN)..

Eur J Hum Genet. 2013 May;21(5):480-6. doi: 10.1038/ejhg.2012.200.

Differential effects of early environmental enrichment on emotionality related behaviours in Huntington's disease transgenic mice.

Renoir T, Pang TY, Mo C, Chan G, Chevarin C, Lanfumey L, Hannan AJ.

J Physiol. 2013 Jan 1;591(1):41-55. doi: 10.1113/jphysiol.2012.239798.

The role of iron imaging in Huntington's disease.

van den Bogaard SJ, Dumas EM, Roos RA.

Int Rev Neurobiol. 2013;110:241-50. doi: 10.1016/B978-0-12-410502-7.00011-9. Review.

Three decades of caring for the Venezuelan Huntington's disease families.

Wexler NS.

Lancet Neurol. 2013 Aug;12(8):738. doi: 10.1016/S1474-4422(13)70170-4. No abstract available.

[The White man's burden - a case study caught between bipolar affective disorder and Huntington's disease].

Nowidi K, Kunisch R, Bouna-Pyrrou P, Meißner D, Hennig-Fast K, Weindl A, Förster S, Neuhann TM, Falkai P, Berger M, Musil R.

Fortschr Neurol Psychiatr. 2013 Jun;81(6):337-45. doi: 10.1055/s-0033-1335040. German.

Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease.

Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RL, Roos RA, Howland D, Detloff PJ, Housman DE, Bates GP.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2366-70. doi: 10.1073/pnas.1221891110.

Difficulty modifying a sustained motor response in prodromal Huntington's disease.

Mickes L, Wixted JT, Peavy GM, Jacobson MW, Goldstein JL, Corey-Bloom J.

J Clin Exp Neuropsychol. 2013;35(1):35-40. doi: 10.1080/13803395.2012.742039.

Mitochondrial permeability transition pore induces mitochondria injury in Huntington disease.

Quintanilla RA, Jin YN, von Bernhardi R, Johnson GV.

Mol Neurodegener. 2013 Dec 11;8:45. doi: 10.1186/1750-1326-8-45.

Thalamic metabolic abnormalities in patients with Huntington's disease measured by magnetic resonance spectroscopy.

Casseb RF, D'Abreu A, Ruocco HH, Lopes-Cendes I, Cendes F, Castellano G.

Braz J Med Biol Res. 2013 Aug;46(8):722-7. doi: 10.1590/1414-431X20132332.

Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.

Giampà C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR.

PLoS One. 2013 May 20;8(5):e64037. doi: 10.1371/journal.pone.0064037. Erratum in: PLoS One. 2016 Nov 23;11(11):e0166102.

Chorea and developmental regression associated with human herpes virus-6 encephalitis.

Pulickal AS, Ramachandran S, Rizek P, Narula P, Schubert R.

Pediatr Neurol. 2013 Mar;48(3):249-51. doi: 10.1016/j.pediatrneurol.2012.11.010.

The role of dopamine and glutamate modulation in Huntington disease.

Mittal SK, Eddy C.

Behav Neurol. 2013;26(4):255-63. doi: 10.3233/BEN-2012-120268. Review.

Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.

Nithianantharajah J, Hannan AJ.

Neuroscience. 2013 Oct 22;251:66-74. doi: 10.1016/j.neuroscience.2012.05.043. Review.

Dopamine receptor autoantibodies correlate with symptoms in Sydenham's chorea.

Ben-Pazi H, Stoner JA, Cunningham MW.

PLoS One. 2013 Sep 20;8(9):e73516. doi: 10.1371/journal.pone.0073516.